XML 145 R132.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT INFORMATION - Revenues by Product Category (Details)
$ in Millions
12 Months Ended
Dec. 31, 2022
USD ($)
product
Dec. 31, 2021
USD ($)
product
Dec. 31, 2020
USD ($)
product
Revenue from External Customer [Line Items]      
Number of products represented of total revenue | product 10 10 10
Revenues $ 8,124 $ 8,434 $ 8,027
Pharmaceuticals      
Revenue from External Customer [Line Items]      
Revenues 3,676 3,763 3,680
Devices      
Revenue from External Customer [Line Items]      
Revenues 1,872 1,903 1,566
OTC      
Revenue from External Customer [Line Items]      
Revenues 1,611 1,532 1,430
Branded and Other Generics      
Revenue from External Customer [Line Items]      
Revenues 887 1,144 1,248
Other revenues      
Revenue from External Customer [Line Items]      
Revenues 78 92 103
Salix      
Revenue from External Customer [Line Items]      
Revenues 2,090 2,074 1,904
Salix | Pharmaceuticals      
Revenue from External Customer [Line Items]      
Revenues 2,090 2,066 1,899
Salix | Devices      
Revenue from External Customer [Line Items]      
Revenues 0 0 0
Salix | OTC      
Revenue from External Customer [Line Items]      
Revenues 0 0 0
Salix | Branded and Other Generics      
Revenue from External Customer [Line Items]      
Revenues 0 0 0
Salix | Other revenues      
Revenue from External Customer [Line Items]      
Revenues 0 8 5
International      
Revenue from External Customer [Line Items]      
Revenues 988 1,166 1,181
International | Pharmaceuticals      
Revenue from External Customer [Line Items]      
Revenues 279 259 255
International | Devices      
Revenue from External Customer [Line Items]      
Revenues 0 0 0
International | OTC      
Revenue from External Customer [Line Items]      
Revenues 151 136 112
International | Branded and Other Generics      
Revenue from External Customer [Line Items]      
Revenues 527 738 775
International | Other revenues      
Revenue from External Customer [Line Items]      
Revenues 31 33 39
Solta Medical      
Revenue from External Customer [Line Items]      
Revenues 300 308 253
Solta Medical | Pharmaceuticals      
Revenue from External Customer [Line Items]      
Revenues 0 0 0
Solta Medical | Devices      
Revenue from External Customer [Line Items]      
Revenues 300 308 253
Solta Medical | OTC      
Revenue from External Customer [Line Items]      
Revenues 0 0 0
Solta Medical | Branded and Other Generics      
Revenue from External Customer [Line Items]      
Revenues 0 0 0
Solta Medical | Other revenues      
Revenue from External Customer [Line Items]      
Revenues 0 0 0
Diversified Products      
Revenue from External Customer [Line Items]      
Revenues 978 1,121 1,274
Diversified Products | Pharmaceuticals      
Revenue from External Customer [Line Items]      
Revenues 826 924 1,020
Diversified Products | Devices      
Revenue from External Customer [Line Items]      
Revenues 0 0 0
Diversified Products | OTC      
Revenue from External Customer [Line Items]      
Revenues 7 7 7
Diversified Products | Branded and Other Generics      
Revenue from External Customer [Line Items]      
Revenues 120 167 219
Diversified Products | Other revenues      
Revenue from External Customer [Line Items]      
Revenues 25 23 28
Bausch + Lomb      
Revenue from External Customer [Line Items]      
Revenues 3,768 3,765 3,415
Bausch + Lomb | Pharmaceuticals      
Revenue from External Customer [Line Items]      
Revenues 481 514 506
Bausch + Lomb | Devices      
Revenue from External Customer [Line Items]      
Revenues 1,572 1,595 1,313
Bausch + Lomb | OTC      
Revenue from External Customer [Line Items]      
Revenues 1,453 1,389 1,311
Bausch + Lomb | Branded and Other Generics      
Revenue from External Customer [Line Items]      
Revenues 240 239 254
Bausch + Lomb | Other revenues      
Revenue from External Customer [Line Items]      
Revenues $ 22 $ 28 $ 31
Revenues | Product Concentration Risk | Customer, Top Ten Products      
Revenue from External Customer [Line Items]      
Concentration risk, percentage 49.00% 43.00% 41.00%